Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humansPhysiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationSynergistic interaction between genetics and disease on pravastatin dispositionSandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity.Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.Integration of Physiologically-Based Pharmacokinetic Modeling into Early Clinical Development: An Investigation of the Pharmacokinetic NonlinearityInteraction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI-based DDIs.Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis.Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sexA mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporineModel-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.Primary hepatocyte cultures as prominent in vitro tools to study hepatic drug transporters.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium.In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.Dealing with the complex drug-drug interactions: towards mechanistic models.The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin.Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method.Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide.Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach.Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development.Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activatedTransporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.Prediction of the Pharmacokinetics of Pravastatin as an OATP Substrate using Plateable Human Hepatocytes with Human Plasma Data and PBPK Modeling.Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast.Response to the Comment on the Article “Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions”Quantitative Prediction of OATP-Mediated Drug-Drug Interactions With Model-Based Analysis of Endogenous Biomarker Kinetics
P2860
Q24273350-32998035-9B10-4867-8D4C-B16D8D70BC76Q27022933-2CD31357-E7C8-48FF-9A6E-B20922D4D953Q28088352-A3A44BA3-C70A-4617-83B1-1F03B94DB0BCQ33786577-662DEF62-82B4-42E2-B4FE-78E702303A48Q34330504-61A70479-F23D-42AA-AF83-3D9999B281DBQ34646772-15DE01E9-DDF4-4AF9-85CC-E27286C3DAF8Q35211432-99DFBAD7-879B-4F59-810D-9FC797F19DA3Q35560052-2DC0C95A-514A-4642-B500-8E4645C34A9BQ35676044-BBC1DCCF-100A-4E1D-AE83-5B565D43887AQ36763108-42114874-11C2-47AC-9F32-617B2F0AFF95Q36972804-2DE76C45-6DFC-4D59-BD90-AE6B44D2A2FBQ37279044-E83B8B15-DA98-4D5C-A830-4105C3BA4A76Q37422685-C85ECACB-8A7E-4B5C-9DDB-4E458209E786Q37470663-660178D6-0087-452D-8A8E-26F1E0D9AC61Q38075057-7BD046D0-4C17-40E1-ABB6-095603B7E8E5Q38077993-CBD8B1E2-9F12-439E-A6CB-F002B0E1B3F4Q38087695-A30893AA-7EC7-449C-AF4C-F78BA49210D0Q38099195-C5F72319-CF74-4AFC-A9B1-3A550FD96BACQ38214334-908F5019-8D59-49FA-B2C8-742C3C4E8420Q38233298-A45095D4-B08D-4D9E-B390-9E7A16B3A311Q38302225-2D7F445D-956E-4B5C-8EFE-FD6E1461735CQ38844656-8D94BD99-724E-480E-A6DF-CB1DF52BC79EQ38855314-BBE53863-8155-41B9-98BB-C9E301289451Q39101424-A4520EFB-8826-49DF-877B-DFFF4065940BQ39178447-CFADF0EA-422D-4E4A-944D-D8757347AB6EQ39212609-97B6AB43-E667-430A-B5D3-7E81EFFF267AQ39773424-F165ECAF-D7B4-43C7-92FE-667E4086BBACQ41150870-F383D104-4F26-4C15-93C4-F61A996A86AEQ41497276-F369F9E0-43E1-4506-9D13-CF59B88EE671Q41768726-A772C10D-2CDB-402A-A812-B1A689DF44B2Q42711587-0AEE6D1D-1C56-4F0B-AE95-D22B39D4F9C2Q45243894-1A3E1653-B371-4990-80C8-ABA3E8EB97B1Q47592224-3BF279BD-9F4A-4A01-94E4-315B11E35D74Q49502999-458783C6-82BC-4D2F-BAEC-6344BCD0A03EQ51485773-0C334253-8FEA-417B-8B9C-7DA24075E724Q57684330-E1217182-8914-4AE6-9A3A-0A1E6B452FF1Q58712139-1E4F4EA0-3C7B-422F-AB64-BD30AC8AD40A
P2860
Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions
description
article
@en
im Mai 2012 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2012
@uk
name
Physiologically Based Modeling ...... ion and Drug-Drug Interactions
@en
Physiologically Based Modeling ...... ion and Drug-Drug Interactions
@nl
type
label
Physiologically Based Modeling ...... ion and Drug-Drug Interactions
@en
Physiologically Based Modeling ...... ion and Drug-Drug Interactions
@nl
prefLabel
Physiologically Based Modeling ...... ion and Drug-Drug Interactions
@en
Physiologically Based Modeling ...... ion and Drug-Drug Interactions
@nl
P2093
P2860
P1476
Physiologically based modeling ...... ion and drug-drug interactions
@en
P2093
Arthur Bergman
John Litchfield
Manthena V S Varma
Theunis C Goosen
P2860
P304
P356
10.1007/S11095-012-0792-7
P50
P577
2012-05-26T00:00:00Z